Prostate Cancer
News and reporting on prostate cancer.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Lantern Pharma Reacquires Irofulven From Allarity Therapeutics; Plans Bladder, Prostate Cancer Trial
In reacquiring the rights to the agent, which it out-licensed in 2015, Lantern is also gaining rights to Allarity's DRP technology to predict patients' responses.
Chinese Regulators Approve Lynparza for BRCA1/2-Mutated mCRPC
China's NMPA granted conditional approval to AstraZeneca and Merck's PARP inhibitor in this setting based on the results of the PROfound trial.
Pfizer Studying Talzenna in Advanced Prostate Cancer Patients With DNA Damage Response Gene Defects
The Phase III trial will randomize metastatic castration-sensitive prostate cancer patients to Talzenna plus Xtandi or just Xtandi.
ASCO Studies Show Impact of Biomarker Testing, Therapy Inequities in Black Men With Prostate Cancer
Two studies highlighted the importance of enrolling Black men in clinical trials to improve outcomes and ensure the efficacy of treatments and tests